Sort
10,766 grants matching “checkpoint inhibitor”
Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer
$619,487Joseph A Califano · University Of California, San Diego · R01 · FY2025 · CA
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
$619,471Beth A. Reboussin · Wake Forest University Health Sciences · U01 · FY2024 · CA
Tailoring CAR T cell therapy for Hodgkin Lymphoma
$619,470Barbara Savoldo · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Project 2: Combination PARPi-BETi to Overcome PARPi Resistance
$619,012Haider Mahdi · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · CA
Impact of Interventions on Clonally Expanded Proviruses and Their RNA Expression
$618,983Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
$618,912Donald W. Kufe · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
$618,854Emese Zsiros · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Innate NLRC4 signaling controls adaptive immune responses
$618,773Fayyaz S. Sutterwala · Cedars-Sinai Medical Center · R01 · FY2023 · AI
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
$618,713Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2023 · CA
Antigen-specific âkick and killâ of the latent HIV reservoir using dendritic cells
$618,659Robbie B Mailliard · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · AI
Pan-Cancer characterization of 3âUTR somatic mutations controlling tumor immune evasion
$618,468Ioannis Vlachos · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
Using the IL-1R1 and its ligands to optimize the T cell immune response to cancer
$618,308Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2025 · CA
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer
$618,273Kian H Lim · Washington University · R01 · FY2023 · CA
Developing a novel combination immunotherapy for triple-negative breast cancer
$618,212Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2024 · CA
Long-Term Cardiovascular Sequelae of Cancer Immunotherapies
$618,167Javid J Moslehi · University Of California, San Francisco · R01 · FY2023 · HL
Glycosylation and Immune Evasion in Urologic Tumors
$618,139Sharon Pitteri · Stanford University · U01 · FY2020 · CA
Triggering Aberrant RNA Processing for RCC Therapy
$618,057William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
Triggering Aberrant RNA Processing for RCC Therapy
$618,056William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
Drug eluting injectable biomaterials for next generation chemoembolization
$617,904Rahmi Oklu · Mayo Clinic Arizona · R01 · FY2025 · CA
Credentialing a Cross-Species Platform to Investigate Cancer Therapy-Associated Cardiovascular Toxicity
$617,870Iris Z Jaffe · Tufts Medical Center · R01 · FY2022 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$617,796Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
$617,796Ernesto Guccione · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$617,715Brent Allen Hanks · Univ Of North Carolina Chapel Hill · R37 · FY2025 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.
$617,631Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2020 · CA
Nutrient Regulation of Cancer Cell Growth
$617,432Heather Christofk · University Of California Los Angeles · R01 · FY2024 · CA